Catalyst Pharmaceuticals, Inc. (CN2.F)

14,89 -0,21 (-1,39%) Börsenschluss: 08:01AM CEST

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 167

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Richard John Daly M.B.A.	President, CEO & Director	62,69k	N/A	1961
Dr. Steven R. Miller Ph.D.	Executive VP, COO & Chief Scientific Officer	814,09k	N/A	1962
Dr. Gary Ingenito M.D., Ph.D.	Chief Medical & Regulatory Officer	746,62k	N/A	1956
Mr. Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	735,98k	N/A	1971
Mr. Michael W. Kalb CPA	Executive VP, Treasurer & CFO	N/A	N/A	1971
Ms. Mary Coleman	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Brian Elsbernd J.D.	Chief Compliance Officer & Chief Legal Officer	286,56k	N/A	1964
Mr. Pete Curry Sr.	Vice President of Sales	N/A	N/A	N/A
Dr. Stanley Iyadurai M.D., Ph.D.	Senior Vice President of Medical Affairs & Drug Discovery	N/A	N/A	N/A
Dr. Preethi Sundaram Ph.D.	Chief Strategy Officer	470,45k	N/A	1976

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 7, Vorstand: 6, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.